Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

Thus far, in part 1 of the TALAPRO-2 trial, data showed that the optimal 0.5 mg dose of talazoparib (Talzenna) was found to be very safe and was associated with preliminary efficacy when in combination with enzalutamide (Xtandi), Agarwal explains.

The ultimate goal of part 2 of this study is to improve survival in these patients, not only in terms of radiographic progression-free survival, but also overall survival. The trial is enrolling more than 800 patients worldwide, and investigators hope to see encouraging data that will change the standard of care for this patient population. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Agarwal on the TALAPRO-2 Trial in mCRPC